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Abstract We have investigated the expression of neuronal-type 
NO synthase I (NOS I) and inducible-type NOS II in guinea pig 
skeletal muscle (diaphragm). Expression of NOS I mRNA and 
protein was highest in muscle of specific pathogen-free animals, 
lower in normally bred animals, and lowest in lipopolysaccharide 
(LPS)-treated animals. NOS II mRNA and protein levels were 
highest in muscle of LPS-treated animals. Elevated NOS activity 
in muscle from LPS-treated animals was less susceptible to the 
NOS I-selective inhibitor NG-nitro-L-arginine. Expressional 
downregulation of NOS I in sepsis may have implications for 
contractile function of skeletal muscle. 
© 1997 Federation of European Biochemical Societies. 
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tricular nuclei of the hypothalamus, and elevated NOS activ-
ity in the posterior pituitary [15]. Upregulation of NOS I 
mRNA was detected in rat sympathetic neurons and central 
motor neurons following axotomy [16]. One report suggested 
that estrogens can upregulate NOS I mRNA in skeletal 
muscle [17]. Developmental regulation of NOS I expression 
has been reported in rat lung and murine skeletal muscle 
[18,19], and Ogura et al. [20] have described induction of 
NOS I expression in the development of neural precursor cells 
isolated from embryonic murine neural tubes. 
In the present study we demonstrate that NOS I mRNA 
and protein are downregulated in guinea pig skeletal muscle 
when the animal is treated with bacterial lipopolysaccharide 
(LPS), a stimulus which has been reported to enhance expres-
sion of inducible-type NOS II in this tissue [8]. 
1. Introduction 
Neuronal-type NO-synthase (NOS I) was first identified in 
rat and porcine brain [1-3], and has subsequently been found 
in spinal cord, peripheral nerves, epithelial cells, and skeletal 
muscle (for review see [4]). In brain, NOS I is mainly a soluble 
enzyme with a molecular mass of 160 kDa [1-3,5]. Expression 
of NOS I in skeletal muscle has been first reported by Nakane 
et al. [6]. Most of the NOS I protein found in skeletal muscle 
is membrane-bound [7,8]. In several reports, the sarcolemmal 
endplate region has been described as the major site of ex-
pression of NOS I in skeletal muscle [8-11]. The molecular 
basis for membrane association of NOS I has recently been 
investigated. The N-terminal region of NOS I contains a se-
quence motif, referred to as GLGF- or PDZ-domain, which 
mediates association of this enzyme with cytoskeletal proteins 
[9,12,13]. 
NOS I is considered a constitutive enzyme, but there are 
some reports of expressional regulation. However, many of 
these stimuli reported to modulate expression are rather 
non-specific. Occlusion of the middle cerebral artery of the 
rat produced an upregulation of NOS I mRNA and immu-
noreactive protein [14]. Chronic salt loading of rats increased 
expression of NOS I mRNA in the supraoptic and paraven-
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2. Materials and methods 
2.1. Animals 
Male Dunkin Hartley guinea pigs (200-250 g; Charles River, Sulz-
feld, Germany) were kept in our animal facilities on regular chow and 
water until the day of the experiment. For treatment of guinea pigs 
with bacterial lipopolysaccharide (LPS), LPS was dissolved in phos-
phate-buffered saline at a concentration of 7.5 mg/ml by thoroughly 
mixing and briefly sonicating the solution. A few hours after treat-
ment with an i.p. injection of LPS (7.5 mg/kg), guinea pigs behaved 
apathetic and started shivering. Animals were sacrificed 6 hours after 
injection of LPS, a time at which high expression of NOS II protein 
has been reported in different tissues of LPS-treated animals [21]. 
'Specific pathogen-free' (SPF) guinea pigs were obtained from Charles 
River, delivered in microorganism-tight containers and sacrificed im-
mediately upon arrival. 
2.2. Ribonuclease protection analyses with guinea pig-specific cRNA 
probes 
Plasmids containing guinea pig specific NOS I, NOS II and (3-actin 
cDNA fragments were generated as previously described [8]. Ribonu-
clease protection analyses were performed according to standard pro-
cedures [22]. Briefly, radiolabeled antisense RNA (cRNA) probes were 
generated by in vitro transcription of 0.5 mg plasmid DNA using T3 
or T7 RNA polymerase (Stratagene) and 90 uCi [a-32P]-UTP per 
reaction. Thereafter, template DNA was degraded by incubation 
with DNase I; labeled cRNA probes were purified on NucTrap probe 
purification columns (Stratagene). For each hybridization 4 (ig 
poly(A)+-enriched RNA [22] from skeletal muscle and control tissues 
(cerebellum of normal animals, and small intestine of LPS-treated 
animals) were incubated overnight at 50°C with 100000 cpm NOS 
cRNA probe and 30000 cpm P-actin cRNA probe. Unhybridized 
probe was digested by treatment with a mixture of RNase A and 
RNase Tl (Boehringer-Mannheim). RNase activity was stopped by 
the addition of proteinase K in a buffer containing 10% sodium do-
decyl sulfate. Protected fragments were extracted with phenol/chloro-
form, precipitated with ethanol and electrophoretic separated in a 
denaturing 6% polyacrylamide gel. DNA fragments derived from 
pG12-Basic restricted with Hintl were labeled with [y-32P]ATP and 
served as size markers. Densitometric analyses of gels were performed 
using a Molecular Imager (Bio-Rad) and results were quantified by 
comparison with the hybridization signal of a P-actin cRNA probe. 
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Fig. 1. Ribonuclease protection analyses for NOS I mRNA (A) and NOS II mRNA (B); B-actin mRNA was used for standardization. Poly 
(A)+RNA was prepared from the diaphragm of specific pathogen-free, normal and LPS-treated guinea pigs, and from control tissues (cerebel-
lum of normal animals and small intestine of LPS-treated animals). Protected RNA fragments were separated on a 6% denaturing polyacryl-
amide gel. Panel (A) shows a hybridization with a cRNA probe specific for guinea pig NOS I mRNA. The protected fragment is 175 nucleo-
tides. Panel (B) shows a hybridization with a cRNA probe specific for guinea pig NOS II mRNA. Here the protected fragment is 239 
nucleotides. Molecular size markers and t-RNA controls (20 u,g RNA/lane) are also shown. NOS I mRNA was detected in the cerebellum (pos-
itive control) and in diaphragm. NOS II mRNA was found in small intestine (positive control) and in diaphragm. Results are representative of 
three independent experiments yielding the same results. 
2.3. Western blotting 
Particulate protein fractions from diaphragm were solubilized with 
the detergent 3-[(3-cholamidopropyl)-dimethylammonio]-l-propane-
sulfonate (CHAPS, 20 mM final concentration) and enriched for 
NOS by 2',5'-ADP Sepharose chromatography [23]. A CHAPS-solu-
bilized homogenate from guinea pig cerebellum and a partially puri-
fied soluble fraction from RAW 264.7 macrophages, induced for 18 h 
with LPS (1 |ig/ml) and interferon-y (100 U/ml), were used as control 
protein preparations. Proteins were separated by denaturing discon-
tinuous polyacrylamide gel electrophoresis (Disc-PAGE) using 7.5% 
resolving gels. Western blotting was performed as described [8]. 
Briefly, blots were incubated with a polyclonal anti-NOS I antibody 
([24]; 1:2000) and a monoclonal anti-NOS II antibody (Transduction 
Laboratories, Lexington, KY; 1:500). After incubation with the sec-
ondary antibody conjugated to alkaline phosphatase, immunoreactive 
proteins were visualized with NBT/X-phosphate (4-nitroblue tetrazo-
lium chloride/5-bromo-4-chloro-3-indolyl-phosphate). 
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2.4. Assay of NOS activity 
The NO-forming capacity of affinity-purified fractions from dia-
phragm muscle was measured by bioassay using RFL-6 rat lung fi-
broblasts, as previously described [25,26]. This assay measures NO-
stimulated cGMP accumulation in these reporter cells. The enzymatic 
reaction was performed on the reporter cells in a volume of 1 ml. The 
reaction mixture contained 100 uM arginine, 100 uM NADPH, 3 uM 
tetrahydrobiopterin, 300 nM FAD, 250 uM glutathione and 500 U/ml 
calmodulin. The reaction was started by the addition of the respective 
protein fraction and was allowed to proceed for 3 min. In NOS in-
hibitor studies, protein preparations (10-25 |ig) were preincubated 
with NG-nitro-L-arginine ( L - N N A ) in Locke's solution [26] at 37°C 
for 5 min. 
3. Results 
3.1. Regulation of NOS I and NOS II mRNAs 
Ribonuclease protection assays with a NOS I cRNA probe 
and mRNA from guinea pig diaphragm revealed a protected 
RNA fragment of the expected molecular size (Fig. 1A). The 
intensity of the signal was strongest in RNA from SPF guinea 
pigs (100%o), lower in RNA from normal animals (68% of 
SPF), and lowest in RNA from LPS-treated animals (36% 
of SPF). Small intestine of LPS-treated animals and cerebel-
lum of normal animals were utilized as control tissues. A 
strong signal was seen in cerebellum of normal animals, but 
none in small intestine from LPS-treated animals (Fig. 1A). 
Using a NOS II cRNA probe, a protected RNA fragment of 
the expected molecular size was detected in skeletal muscle, 
with the highest intensity in muscle from LPS-treated animals 
(Fig. IB). Small intestine from LPS-treated animals (used as a 
positive control) gave a strong NOS II signal, whereas no 
significant signal was found in cerebellum from normal ani-
mals (negative control) (Fig. IB). 
3.2. Regulation of NOS I and NOS II protein 
In Western blots with particulate protein fractions from 
guinea pig diaphragm, significant NOS I immunoreactivity 
was detected in protein preparations from SPF animals (Fig. 
2A). This signal was weaker in muscle from normal animals 
and still less in muscle from LPS-treated guinea pigs (Fig. 
2A). Muscle NOS I migrated with the expected molecular 
mass of about 160 kDa which was not different from the 
NOS I in protein preparations from guinea pig cerebellum 
(positive control) (Fig. 2A). Also, NOS II immunoreactivity 
was detected in the particulate fractions of muscle from the 
different types of animals (Fig. 2B). Marked staining was 
present in muscle from SPF- and normal animals; the signal 
was significantly increased in muscle from LPS-treated ani-
mals. Interestingly, muscle NOS II migrated slightly above 
the immunoreactive band obtained with the soluble fraction 
from induced RAW 264.7 macrophages (Fig. 2B). No relevant 
signals of NOS I or NOS II immunoreactivities were found in 
the soluble protein fractions of skeletal muscle (n = 3, not 
shown). 
3.3. Regulation of NOS activity 
Specific NOS activity was lowest in muscle from SPF ani-
mals and increased more than 2-fold in muscle from LPS-
treated animals (Table 1). In further experiments, the inhib-
ition of muscle NOS activities by L - N N A and aminoguanidine 
was investigated. Based on previous reports, L - N N A is about 
ten times more potent in inhibiting NOS I activity compared 
with NOS II activity [27,28]. L - N N A produced significantly 
less NOS inhibition in muscle protein preparations from 
LPS-treated animals than normal or SPF animals (Table 1). 
Aminoguanidine is usually considered a selective inhibitor of 
NOS II [28]. However, as previously reported [8], guinea pig 
muscle NOS was only marginally inhibited by aminoguani-
dine (up to 300 uM, not shown). This is in agreement with 
a report by Nakane et al. [27] demonstrating that aminogua-
nidine has very low inhibitory potency and lacks isoform se-
lectivity with human NOS. 
4. Discussion 
The major finding of the current study is that exposure of 
animals to bacterial LPS not only upregulates NOS II expres-
sion, but also downregulates NOS I expression in skeletal 
muscle (diaphragm) of guinea pigs. This finding is surprising 
because NOS I is usually considered a constitutively expressed 
gene. Upregulation of NOS I gene expression has previously 
been reported in nerves in response to traumatic stimuli 
[14,16] and in lung, nerve cells and skeletal muscle cells during 
maturation [18-20]. To our knowledge, downregulation of 
NOS I in response to a specific agent has not yet been de-
scribed; but a recent report suggested that there is a defect in 
NOS I expression in dystrophin-deficient muscular dystrophy 
[19]. 
Evidence has been presented for an alternatively spliced 
NOS I in rat skeletal muscle. This muscle NOS I was found 
to be slightly larger than brain NOS I owing to a 34-amino 
acid (102-base pair) insert between amino acids 839 and 840 
of the brain form [29]. The muscle isoform had similar cata-
lytic activity as brain NOS I [29]. In our study, we did not 
specifically search for a muscle isoform. However, in Western 
blots, guinea pig muscle NOS I migrated with a molecular 
mass which was not different from NOS I in preparations 
Table 1 
Specific NOS activities in particulate fractions of guinea pig skeletal muscle, and their inhibition by the NOS I-selective inhibitor NG-nitro-L-
arginine 
Inhibitor treatment NOS activities (cGMP/g tissue)" 
SPF animals Normal animals LPS-treated animals 
None (basal activity) 
3 uM L - N N A 
30 |xM L - N N A 
10.8 ±0.7 17.9 ±0.5 24.1 ±0.9 
% residual activity following inhibitor treatment 
7.9 ±0.6 
0.3 ±0.2 
7.2 ±0.8 
1.7 ±0.2 
16.3 ±1.2 
2.9 ±0.3 
Activity was measured by the stimulation of soluble guanylyl cyclase in RFL-6 reporter cells as described in Section 2. Results represent ± SEM of 
four determinations. 
aThese activities were set 100% in subsequent studies with L-NNA. 
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Fig. 2. Western blots of particulate protein fractions from diaphragm muscle of specific pathogen-free, normal and LPS-treated guinea pigs. 
Electrophoreses were performed in 7.5% polyacrylamide resolving gels and blots were immunostained with anti-NOS I antibody (A) or anti-
NOS II antibody (B). Positive control proteins were included (CHAPS-solubilized homogenate of guinea pig cerebellum for NOS I, and parti-
ally purified soluble fraction from LPS-induced RAW 264.7 macrophages for NOS II; 100 ug protein/lane and 10 iig protein/lane, respectively). 
Diaphragm muscle samples were applied at 10 ug protein/lane. Results are representative of four independent experiments with identical re-
sults. 
from guinea pig cerebellum (Fig. 2A), murine or porcine cer-
ebellum (not shown). Thus, either a separate muscle form 
does not occur in guinea pig diaphragm, or its difference in 
molecular weight is too small to be detected in our Western 
blots. 
On the other hand, the NOS II immunoreactivity found in 
guinea pig skeletal muscle was slightly more massive than the 
control NOS II obtained from induced RAW 264.7 macro-
phages (Fig. 2B). In RAW 264.7 cells, NOS II is primarily 
soluble, whereas in striated muscle most of the enzyme is 
particulate. The increase in molecular weight could reflect 
posttranslational modifications responsible for the membrane 
association of the NOS II in muscle. Thoenes et al. [30] found 
a similar shift in the molecular weight of NOS II in homoge-
nates of heart muscle samples from patients with sepsis, rela-
tive to affinity-purified NOS II from RAW 264.7 macro-
phages. Furthermore, Vodovotz et al. [31] reported a 4.5 
kDa increase in the molecular mass of the membrane-associ-
ated NOS II in primary macrophages, compared to NOS II in 
the soluble fraction of these cells. However, the posttransla-
tional modifications responsible for the membrane association 
of NOS II (and the increase in apparent molecular mass) have 
not yet been identified. NOS II contains five pairs of di-ly-
sines, a motif that may undergo e-NH2 myristylation [31]. 
Moreover, NOS II can be phosphorylated on tyrosine residues 
[32] and probably serine/threonine residues [31]. 
The functions of NO in different areas of skeletal muscle 
are still largely unclear. Skeletal muscle represents an impor-
tant source of NOS I expression [6-9], and the highest enzyme 
levels are found at the neuromuscular endplate [8,10,11,13]. In 
the CNS, NO has been shown to regulate synaptic connectiv-
ity during development [33], and synaptic plasticity in the 
adult [34]. Also at developing neuromuscular synapses, NO 
can serve as a retrograde messenger mediating presynaptic 
suppression [35]. If similar mechanisms were active in mature 
striated muscle, a downregulation of membrane-associated 
NOS I by LPS could result in an improved synaptic trans-
mission. However, the NOS I downregulation in response to 
LPS was accompanied by an upregulation of the NOS II iso-
form. Even though this is likely to occur in different cell 
compartments, the NOS II-derived NO production may still 
mask a reduced NO production by NOS I. Indeed, recent 
findings in our laboratory indicate that contractile function 
is depressed in striated muscles from LPS-treated animals 
[8]. Furthermore, we and others found NO donor compounds 
to reduce, and NOS inhibitors to improve contractile force 
[7,8]. The molecular mechanisms of this negative regulation 
of contraction by NO are unknown. In mitochondria isolated 
from rat brain or heart, NO has been reported to reduce 
respiration rate by reversibly inhibiting the activity of cyto-
chrome c oxidase [36,37]. Similarly, in primary astrocyte cul-
tures induced with LPS/interferon-y, NOS II-generated NO 
has been shown to significantly decrease the activity of cyto-
chrome c oxidase [38]. Other evidence suggests that NO could 
reduce contractile force of skeletal muscle by inhibiting the 
ryanodine receptor calcium release channel [39]. 
In conclusion, LPS treatment of guinea pigs leads to an 
overexpression of NOS II in skeletal muscle. Interestingly, 
this tissue has been found to express this isoform already 
under basal conditions [8]. On the other hand, the NOS I 
isoform which is also present in muscle tissue, is significantly 
downregulated following treatment of guinea pigs with LPS. 
Additional studies are needed to characterize the functional 
consequences of this expressional regulation. 
Acknowledgements: This study was supported by Grants Fo 144/3-1, 
Fo 144/4-1 and Cl 100/3-1 from the Deutsche Forschungsgemein-
schaft, Bonn, Germany, and a Grant from the Ministry of the Envi-
ronment of the State of Rhineland-Palatinate, Mainz, Germany. 
References 
[1] Mayer, B., John, M. and Bohme, E. (1990) FEBS Lett. 277, 215-
219. 
[2] Bredt, D.S. and Snyder, S.H. (1990) Proc. Natl. Acad. Sci. USA 
87, 682-685. 
[3] Schmidt, H.H.H.W., Pollock, J.S., Nakane, M., Gorsky, L.D., 
/. Gath et al.lFEBS Letters 410 (1997) 319-323 323 
Forstermann, U. and Murad, F. (1991) Proc. Natl. Acad. Sci. 
USA 88, 365-369. 
Forstermann, U., Gath, I., Schwarz, P., Closs, E.I. and Kleinert, 
H. (1995) Biochem. Pharmacol. 50, 1321-1332. 
Bredt, D.S., Hwang, P.M., Glatt, C.E., Lowenstein, C , Reed, 
R.R. and Snyder, S.H. (1991) Nature 351, 714-718. 
Nakane, M., Schmidt, H.H.H.W., Pollock, J.S., Forstermann, U. 
and Murad, F. (1993) FEBS Lett. 316, 175-180. 
Kobzik, L., Reid, M.B., Bredt, D.S. and Stamler, J.S. (1994) 
Nature 372, 546-548. 
Gath, I., Closs, E.I., Godtel-Armbrust, U., Schmitt, S., Nakane, 
M., Wessler, I. and Forstermann, U. (1996) FASEB J. 10, 1614-
1620. 
Brenman, J.E. et al. (1996) Cell 84, 757-767. 
Kusner, L.L. and Kaminski, H.J. (1996) Brain Res. 730, 238-242. 
Oliver, L., Goureau, O., Courtois, Y. and Vigny, M. (1996) Neu-
roreport 7, 924-926. 
Hendriks, W. (1995) Biochem. J. 305, 687-688. 
Brenman, J.E., Chao, D.S., Xia, H.H., Aldape, K. and Bredt, 
D.S. (1995) Cell 82, 743-752. 
Zhang, Z.G., Chopp, M., Gautam, S., Zaloga, C , Zhang, R.L., 
Schmidt, H.H.H.W., Pollock, J.S. and Forstermann, U. (1994) 
Brain Res. 654, 85-95. 
Kadowaki, K., Kishimoto, J., Leng, G. and Emson, P.C. (1994) 
Endocrinology 134, 1011-1017. 
Klimaschewski, L., Obermuller, N , Majewski, M., Bachmann, S. 
and Heym, C. (1996) Cell Tissue Res. 285, 419^*25. 
Weiner, C.P., Lizasoain, I., Baylis, S.A., Knowles, R.G., Charles, 
I.G. and Moncada, S. (1994) Proc. Natl. Acad. Sci. USA 91, 
5212-5216. 
North, A.J., Star, R.A., Brannon, T.S., Ujiie, K., Wells, L.B., 
Lowenstein, C.J., Snyder, S.H. and Shaul, P.W. (1994) Am. J. 
Physiol. 266, L635-L641. 
Chang, W.J. et al. (1996) Proc. Natl. Acad. Sci. USA 93, 9142-
9147. 
Ogura, T., Nakayama, K., Fujisawa, H. and Esumi, H. (1996) 
Neurosci. Lett. 204, 89-92. 
Salter, M., Knowles, R.G. and Moncada, S. (1991) FEBS Lett. 
291, 145-149. 
[22] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Cold Spring 
Harbor Laboratory Press. Cold Spring Harbor, NY. 
[23] Forstermann, U. and Gath, I. (1996) in: Methods in Enzymology 
- Nitric Oxide (Abelson, J.N. and Melvin, I.S., Eds.), vol. 268, 
pp. 334-339, Academic Press, Orlando, FL. 
[24] Schmidt, H.H.H.W., Gagne, G.D., Nakane, M., Pollock, J.S., 
Miller, M.F. and Murad, F. (1992) J. Histochem. Cytochem. 
40, 1439-1456. 
[25] Forstermann, U., Pollock, J.S., Schmidt, H.H.H.W., Heller, M. 
and Murad, F. (1991) Proc. Natl. Acad. Sci. USA. 88, 1788-
1792. 
[26] Ishii, K., Sheng, H., Warner, T.D., Forstermann, U. and Murad, 
F. (1991) Am. J. Physiol. 261, H598-H603. 
[27] Nakane, M. et al. (1995) Biochem. Biophys. Res. Commun. 206, 
511-517. 
[28] Nakane, M., Klinghofer, V., Kuk, J.E., Donnelly, J.L., Budzik, 
G.P., Pollock, J.S., Basha, F.Z. and Carter, G.W. (1995) Mol. 
Pharmacol. 47, 831-834. 
[29] Silvagno, F., Xia, H.H. and Bredt, D.S. (1996) J. Biol. Chem. 
271, 11204-11208. 
[30] Thoenes, M., Forstermann, U., Tracey, W.R., Bleese, N.M., 
Nussler, A.K., Scholz, H. and Stein, B. (1996) J. Mol. Cell. 
Cardiol. 28, 165-169. 
[31] Vodovotz, Y., Russell, D., Xie, Q.W., Bogdan, C. and Nathan, 
C. (1995) J. Immunol. 154, 2914-2925. 
[32] Pan, J.M., Burgher, K.L., Szczepanik, A.M. and Ringheim, G.E. 
(1996) Biochem. J. 314, 889-894. 
[33] Wu, H.H., Williams, C.V. and McLoon, S.C. (1994) Science 265, 
1593-1596. 
[34] Schuman, E.M. and Madison, D.V. (1991) Science 254, 1503-
1506. 
[35] Wang, T., Xie, Z.P. and Lu, B. (1995) Nature 374, 262-266. 
[36] Lizasoain, I., Moro, M.A., Knowles, R.G., Darleyusmar, V. and 
Moncada, S. (1996) Biochem. J. 314, 877-880. 
[37] Borutaite, V. and Brown, G.C. (1996) Biochem. J. 315, 295-299. 
[38] Bolanos, J.P., Peuchen, S., Heales, S.J., Land, J.M. and Clark, 
J.B. (1994) J. Neurochem. 63, 910-916. 
[39] Meszaros, L.G., Minarovic, I. and Zahradnikova, A. (1996) 
FEBS Lett. 380, 49-52. 
